ZAYNAB SAID: Open Payments
NPI 1568047512 · DES MOINES, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$807 in 44 payments from 16 companies in 2025. Trend: 2023 $1,057 · 2024 $750 · 2025 $807
Food & beverage: $807
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $221 |
| Novo Nordisk Inc | 6 | $116 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $109 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Janssen Pharmaceuticals, Inc | 2 | $44 |
| AstraZeneca Pharmaceuticals LP | 2 | $38 |
| Lilly USA, LLC | 2 | $35 |
| Astellas Pharma US Inc | 1 | $33 |
| Axsome Therapeutics, Inc. | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
Products named: VRAYLAR, CAPLYTA, REXULTI, SPRAVATO, Ozempic, Wegovy, UBRELVY, Veozah.
Industry payments across IA — which companies pay providers there.
